Modulation of copper transporters in protection against cisplatin-induced cochlear hair cell damage

Journal of Otology

Volumn 6, Issue 2, 2011, Pages 51-59

  Jing chun, He ^a,b,d   Da lian, Ding ^a,b,c   Dong zhen, Yu ^a,b,c   Hai yan, Jiang ^a   Shan kai, Yin ^b,c   Salvi, Richard ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c Oriental Institute of Otolaryngology in Shanghai   (China)

^d SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Cisplatin; cochlear hair cell; copper transporter; ototoxicity

Indexed keywords

EID: 85071924726     PISSN: None     EISSN: 16722930     Source Type: Journal    
DOI: 10.1016/S1672-2930(11)50022-4     Document Type: Article

References (31)

1. Chu, G., Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 269:2 (1994), 787–790.
2. Laurent, G., Erickson, L.C., Sharkey, N.A., et al. DNA cross-linking and cytotoxicity induced by cis-diamminedichloroplatinum(II) in human normal and tumor cell lines. Cancer Res 41:9 Pt1 (1981), 3347–3351.
3. Cepero, V., Garcia-Serrelde, B., Moneo, V., et al. Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription. Clin Transl Oncol 9:8 (2007), 521–530.
4. Aggarwal, S.K., Fadool, J.M., Cisplatin and carboplatin induced changes in the neurohypophysis and parathyroid, and their role in nephrotoxicity. Anticancer Drugs 4:2 (1993), 149–162.
5. Holmes, J., Stanko, J., Varchenko, M., et al. Comparative neurotoxicity of oxaliplatin, cisplatin, and ormaplatin in a Wistar rat model. Toxicol Sci. 46:2 (1998), 342–351.
6. Furue, H., Late effects of cancer chemotherapy. Gan To Kagaku Ryoho. 14:4 (1987), 987–993.
7. Zhang, B., Ramesh, G., Norbury, C.C., et al. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int. 72:1 (2007), 37–44.
8. Martins, N.M., Santos, N.A., Curti, C., et al. Cisplatin induces mitochondrial oxidative stress with resultant energetic metabolism impairment, membrane rigidification and apoptosis in rat liver. J Appl. Toxicol. 28:3 (2008), 337–344.
9. Schweitzer, V.G., Cisplatin-induced ototoxicity: the effects of pigmentation and inhibitory agents. Laryngoscope 103:4 Pt2 (1993), 1–52.
10. Markman, M., Toxicities of the platinum antineoplastic agents. Expert Opin Drug Saf. 2:6 (2003), 597–607.
11. Ding, D., Jiang, H., Wang, P., et al. Cell death after co-administration of cisplatin and ethacrynic acid. Hear Res 226:1–2 (2007), 129–139.
12. Ding, D., Qi, W., Zhang, M., et al. Cisplatin and its ototoxicity. Chinese Journal of Otology 6:2 (2008), 125–133.
13. Ding, D., He, J., Allman, B.L., et al. Cisplatin ototoxicity in rat cochlear organotypic cultures. Hear Res. 282:1–2 (2011), 196–203.
14. Ding, D., Allman, B., Sh, Yin, et al. Cisplatin ototoxicity. Hearing Loss Classification, Causes and Treatment, Chapter 2. 2011, 2011, Nova Science Publishers, Inc, 39–63.
15. Li, Y., Ding, D., Jiang, H., et al. Co-administration of cisplatin and furosemide causes rapid and massive loss of cochlear hair cells in mice. Neurotox Res. 20:4 (2011), 307–319.
16. Clerici, W.J., Hensley, K., DiMartino, D.L., et al. Direct detection of ototoxicant-induced reactive oxygen species generation in cochlear explants. Hear Res 98:1–2 (1996), 116–124.
17. Potapova, O., Haghighi, A., Bost, F., et al. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem 272 (1997), 14041–14044.
18. Ding, D., Wang, P., Jiang, H., et al. Gene expression in cisplatin ototoxicity and protection with p53 inhibitor. Chinese Journal of Otology. 4:2 (2009), 15–24.
19. Zhang, M., Liu, W., Ding, D., et al. Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience 120:1 (2003), 191–205.
20. Hanigan, G.H., Lykissa, E.D., Townsend, D.W., et al. Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin. Am J Pathol. 159:5 (2001), 1889–1894.
21. Ishida, S., Lee, J., Thiele, D.J., et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 99:22 (2002), 14298–14302.
22. Katano, K., Safaei, R., Samimi, G., et al. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 64:2 (2003), 466–473.
23. Katano, K., Safaei, R., Samimi, G., et al. Confocal microscopic analysis of the interaction between cisplatin and the copper transporter ATP7B in human ovarian carcinoma cells. Clin Cancer Res 10:13 (2004), 4578–4588.
24. Wang, D., Lippard, S.J., Cellular processing of platinum anticancer drugs. Nature Reviews 4 (2005), 307–320.
25. Komatsu, M., Sumizawa, T., Mutoh, M., et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated withcisplatin resistance. Cancer Res 60:5 (2000), 1312–1316.
26. Safaei, R., Role of copper transporters in the uptake and efflux of platinum containing drugs. Cancer Lett 234:1 (2006), 34–39.
27. Samimi, G., Kishimoto, S., Manorek, G., et al. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin. Cancer Chemother Pharmacol 59:3 (2007), 301–312.
28. Safaei, R., Howell, S.B., Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 53:1 (2005), 13–23.
29. Hannemann, J., Baumann, K., Nephrotoxicity of cisplatin, carboplatin and transplatin. Arch Toxicology 64 (2003), 393–400.
30. Chiu, L.L., Cunningham, L.L., Raible, D.W., et al. Using the zebrafish lateral line to screen for ototoxicity. J Assoc Res Otolaryngol 9 (2008), 178–190.
31. Katsuda, H., Yamashita, M., Katsura, H., et al. Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. BioPharmBull. 33:11 (2010), 1867–1871.